A study of the efficacy and safety of RO4917523 in patients with Fragile X Syndrome

Registry ID

EUCTR2011-004349-42

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

F. Hoffmann-La Roche Ltd.

Start date

2012-05-23

Completion date

2014-04-04

Last update

2026-08-16

Conditions

• Fragile X Syndrome (FXS)

Summary

• To evaluate the efficacy of 12-week treatment with RO4917523 in patients with Fragile X Syndrome (FXS) as measured by the ADAMS total score • To evaluate the safety and tolerability of 12-week treatment with RO4917523 in patients with FXS

Locations

• , , Spain
• , , Sweden
• , , UK

Related clinical trials

• The Neurocognitive Bases of Trust in Intellectual Disability
• Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X Syndrome
• Optical Imaging in X-linked Disorders.
• Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders
• Group CBT in Adolescents With Fragile X Syndrome and in Adolescents With Autism Spectrum Disorder

View on source registry